Early data suggests that new multicancer early detection (MCED) tests, such as CanScan, MERCURY, and OncoSeek, show promise in identifying cancers without routine screening options. These tests aim to accurately identify multiple cancer types with a single blood draw. CanScan covers two-thirds of new cancer cases globally and has shown promising sensitivity and specificity rates. MERCURY, another MCED test, has demonstrated high accuracy in detecting cancer signals and predicting the tissue of origin. OncoSeek, an affordable MCED test, utilizes protein tumor markers for cancer detection and provides a low-cost screening option for low- and middle-income countries. Further validation and research are needed to determine the clinical utility and optimal use of these tests.
Source link
No Routine Cancer Screening Option? New MCED Tests May Help
